Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Alkylating agents
PLDR + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial is a Phase I study testing whether Pulsed Low Dose Radiation (PLDR) can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT) for non-small cell lung cancer or esophageal cancer while maintaining similar efficacy.
Platinum-based Chemotherapy
Immunotherapy + Chemoradiation for Gastroesophageal Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial will test if giving patients anti-PD-1 or anti-PD1/anti LAG-3 before surgery, along with chemoradiation, is safe and improves survival in patients with resectable distal esophageal/gastroesophageal junction cancer.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
Sacituzumab + Pembrolizumab + Chemotherapy for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing a new combination of drugs for the treatment of advanced stomach, esophageal, or gastroesophageal junction cancer. The trial has two phases to evaluate the safety and effectiveness of
Monoclonal Antibodies
Combination Therapies for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing two different combinations of drugs to see which one is safer and more effective for treating advanced stomach, esophageal, or gastroesophageal junction cancer in participants who have not responded
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Platinum Coordination Complex
mFOLFIRINOX for Stomach Cancer
Recruiting3 awardsPhase 4
Chicago, Illinois
This trial is studying how well a combination of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin works in treating patients with gastroesophageal or stomach cancer.
Radiation
Chemoradiotherapy for Esophageal Cancer
Recruiting1 awardPhase 2
Calgary, Alberta
This trial tests if adding certain chemotherapy drugs to radiation therapy can better relieve swallowing difficulties and improve quality of life for patients with advanced esophageal cancer who can't undergo surgery. These drugs are commonly used in treatment for esophageal cancer and have shown promising results in various studies.
Trials for Squamous Cell Carcinoma Patients
Monoclonal Antibodies
Sacituzumab + Pembrolizumab + Chemotherapy for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing a new combination of drugs for the treatment of advanced stomach, esophageal, or gastroesophageal junction cancer. The trial has two phases to evaluate the safety and effectiveness of
Monoclonal Antibodies
Combination Therapies for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing two different combinations of drugs to see which one is safer and more effective for treating advanced stomach, esophageal, or gastroesophageal junction cancer in participants who have not responded
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Platinum Coordination Complex
mFOLFIRINOX for Stomach Cancer
Recruiting3 awardsPhase 4
Chicago, Illinois
This trial is studying how well a combination of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin works in treating patients with gastroesophageal or stomach cancer.
Trials for HER2 Positive Patients
Chemotherapy
Pembrolizumab + Trastuzumab + Chemotherapy for Gastric Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial will compare the efficacy of two different treatments for HER2-positive gastric cancer. The first treatment is pembrolizumab in combination with standard chemotherapy, and the second is trastuzumab in combination with standard chemotherapy. The hypothesis of the study is that pembrolizumab is superior to trastuzumab in terms of progression free survival and overall survival.
Topoisomerase I inhibitor
Berzosertib + Irinotecan for Gastric Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of berzosertib and irinotecan in patients with advanced gastric or gastroesophageal junction cancer. Berzosertib blocks enzymes needed for cancer growth, and irinotecan kills or stops the spread of cancer cells. Irinotecan has been used in various combinations for treating advanced gastric and gastroesophageal cancers, showing some efficacy but not proving superior to other treatments. The goal is to find a more effective treatment for these difficult-to-treat cancers.
Enzyme Inhibitor
Ceralasertib + Trastuzumab Deruxtecan for Solid Tumors
Recruiting1 awardPhase 1
Los Angeles, California
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.
Phase 3 Trials
Chemotherapy
Pembrolizumab + Trastuzumab + Chemotherapy for Gastric Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial will compare the efficacy of two different treatments for HER2-positive gastric cancer. The first treatment is pembrolizumab in combination with standard chemotherapy, and the second is trastuzumab in combination with standard chemotherapy. The hypothesis of the study is that pembrolizumab is superior to trastuzumab in terms of progression free survival and overall survival.
Antimetabolites
Chemotherapy + Radiotherapy for Esophageal and Gastric Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying how well adding radiotherapy to the usual chemotherapy treatment works compared to the usual treatment alone in treating patients with esophageal and gastric cancer.
Taxane-based Chemotherapy
Pembrolizumab + Lenvatinib + Chemo for Esophageal Cancer
Recruiting2 awardsPhase 3
Worcester, Massachusetts
This trial tests a new combination of drugs and chemotherapy for advanced esophageal cancer. It targets patients whose cancer has spread and who need effective first-line treatment. The treatment works by enhancing the immune system, blocking cancer growth, and killing cancer cells.
Trials With No Placebo
Monoclonal Antibodies
Sacituzumab + Pembrolizumab + Chemotherapy for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing a new combination of drugs for the treatment of advanced stomach, esophageal, or gastroesophageal junction cancer. The trial has two phases to evaluate the safety and effectiveness of
Monoclonal Antibodies
Combination Therapies for Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Grand Rapids, Michigan
This trial is testing two different combinations of drugs to see which one is safer and more effective for treating advanced stomach, esophageal, or gastroesophageal junction cancer in participants who have not responded
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Platinum Coordination Complex
mFOLFIRINOX for Stomach Cancer
Recruiting3 awardsPhase 4
Chicago, Illinois
This trial is studying how well a combination of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin works in treating patients with gastroesophageal or stomach cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.